Pragmatic Clinical Trials: US Payers' Views on Their Value
Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
Racial Variation in the Cost-effectiveness of Chemotherapy for Prostate Cancer
The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.
Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer
Among Medicare enrollees with metastatic colorectal cancer, the use of newer chemotherapy agents was lower for African American patients and for older patients.
Healthcare Utilization and Cost Effects of Prior Authorization for Pregabalin in Commercial Health Plans
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Effects of a Medicaid Prior Authorization Policy for Pregabalin
State Medicaid programs’ pregabalin prior authorization accomplished the objective of lower pregabalin utilization; the unintended effects were increased opioid use and increased disease-related healthcare costs.
Introduction
The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific Approach
Formulary Tier Placement for Commonly Prescribed Branded Drugs: Benchmarking and Creation of a Preferred Placement Index
Drug Therapy Persistence and Stroke Recurrence
New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatment Costs
Impact of an Educational Intervention for Secondary Prevention of Myocardial Infarction on Medicaid Drug Use and Cost
Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population
Overview of Cancer Economics